MRI in Multiple Myeloma: Analysis of the Axial Skeleton Versus Whole Body. What is the Required Analysis?
NCT ID: NCT03618212
Last Updated: 2021-08-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
12 participants
OBSERVATIONAL
2018-12-21
2020-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Multiple Myeloma Minimal Residual Disease
NCT02627261
Multiple Myeloma Patient Registry
NCT03180853
Somatostatin Receptors Imaging in Relapsing and Refractory Multiple Myeloma Patients
NCT04379817
Place of the Hevylite Test in the Evaluation of MRD in Myeloma
NCT03702088
Stopping Maintenance Therapy in People With Multiple Myeloma in MRD-Negative Remission
NCT04221178
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Myeloma patients
MRI
Skeletal MRI and pelvic and spinal MRI
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MRI
Skeletal MRI and pelvic and spinal MRI
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The patient must be a member or beneficiary of a health insurance plan
* The patient is at least 18 years old
* Patient has been diagnosed with multiple myeloma (\> 10% medullary plasma cells + monoclonal protein) or symptomatic myeloma (myeloma + CRAB symptoms (hypercalcemia, renal failure, anemia, bone lesions), or indolent myeloma (myeloma with symptomatic criteria).
Exclusion Criteria
* It is impossible to give the subject informed information
* The patient is under safeguard of justice or state guardianship
* The patient is pregnant or breast feeding
* The patient has an absolute contra-indication for MRI (pace-maker, claustrophobic patient, metal heart valve)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Universitaire de Nīmes
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ahmed Larbi, MD
Role: PRINCIPAL_INVESTIGATOR
CHU Nimes
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU Montpellier
Montpellier, , France
CHU Nimes
Nîmes, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AOIGCSMERRIL/2016/AL-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.